Belgium· BE-AMP-SAM553795-00
Vitrakvi 100 mg
A larotrectinib product containing larotrectinib sulfate, registered in Belgium by Bayer. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Larotrectinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EX12 (larotrectinib), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Larotrectinib · ATC L01EX12
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of larotrectinib costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Larotrectinib · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$254.41
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Larotrectinib Sulfate
- Manufacturer
- Bayer
- Country
- Belgium (BE)
- ATC code
- L01EX12
- ATC class
- Larotrectinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 5
- be_apb7729635
- be_apb4177143
- be_apb4581484
- be_apb7736119
- be_apb7742760
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
527 interactions on record for larotrectinib.
Graded by severity as the source publishes them — 55 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Larotrectinib · interactions on record
527 records
- 55 severe
- 456 moderate
- 16 minor
Most severe, free to view
- LonafarnibA16AX20severe
- ConivaptanC03XA02severe
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Larotrectinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandVITRAKVIBayer AG
- United StatesVITRAKVILoxo Oncology, Inc.
- CzechiaVITRAKVIBayer AG, Leverkusen
- SpainVITRAKVI 100 MG CAPSULAS DURASBayer Ag
- FranceVITRAKVI 100 mg, gélulesBAYER AG (ALLEMAGNE)
- CanadaVITRAKVIBAYER INC
- IcelandVITRAKVIBayer AG
- NetherlandsVitrakvi 100 mg, harde capsulesBayer AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vitrakvi
- Liechtenstein · Vitrakvi
- Norway · Vitrakvi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6300d0f4-5b45-46f4-9635-c2c20246d4cd GET /v1/drugs/6300d0f4-5b45-46f4-9635-c2c20246d4cd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, hard",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Vitrakvi 100 mg",
"name_fr": "Vitrakvi 100 mg",
"name_nl": "Vitrakvi 100 mg",
"amp_code": "SAM553795-00",
"strengths": [
"100.0000"
],
"pack_count": 3,
"substances": [
"Larotrectinib Sulfate",
"Larotrectinib",
"Propylene Glycol"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Larotrectinib",
"authorisation_numbers": [
"EU/1/19/1385/002"
]
}See everything about larotrectinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.